Jazz Pharmaceuticals JAZZ Proceeds from sale of assets
Proceeds from sale of assets at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfOtherProductiveAssets.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's proceeds from sale of assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Jazz Pharmaceuticals's proceeds from sale of assets?
- Jazz Pharmaceuticals (JAZZ) reported proceeds from sale of assets of $200M in Q1 2026.
- What does proceeds from sale of assets mean?
- Cash received from selling company assets.
- How do you interpret proceeds from sale of assets?
- Higher proceeds indicate successful asset optimization or a shift in strategic focus, providing liquidity for other investments.
- How does proceeds from sale of assets compare across companies?
- Varies significantly based on corporate restructuring and portfolio management cycles.